This study focuses on treating children, adolescents, and young adults with Acute Lymphoblastic Leukemia, which is a type of cancer that affects the blood and bone marrow. The research specifically targets patients with certain genetic markers, known as BCR::ABL1-positive or Ph-like, where the cancer cells have specific changes in their DNA. This study is for patients whose disease has either returned after previous treatment, which is called relapsed, or has not responded to initial treatments, which is called refractory.

The purpose of the study is to evaluate the safety and effectiveness of a combination of treatments. The experimental treatment includes the drug asciminib, which is taken by mouth, alongside chemotherapy, a type of treatment using strong medicines to kill cancer cells. Following this, the drug blinatumomab, which is given through an IV infusion, may be used. Other medications that may be part of the background care include vincristine sulfate, dexamethasone, cytarabine, methotrexate, hydrocortisone, and prednisolone acetate.

The study is divided into different stages to find the most appropriate dose of the medicine. In the first stage, researchers look at how the body reacts to different amounts of the drug to ensure safety. In the second stage, the focus shifts to determining how many patients achieve complete remission, a state where all signs of cancer have disappeared. Throughout the process, doctors will monitor for any side effects or changes in health to ensure the treatment is managed carefully.